How to Build an Accretion/Dilution Analysis Slide

When a CEO pitched his board on an acquisition, he opened with the accretion/dilution slide. Year 1 showed dilution of 15%. The board immediately shifted to skepticism: "You're destroying shareholder value?" It took 45 minutes of explanation to reset context: Year 1 was being burdened by integration costs and financing drag; Years 2-3 showed strong accretion; over a five-year hold, the deal was highly accretive.

He should have led differently. The slide itself was sound, but it was sequenced wrong and framed worse. Accretion/dilution analysis is powerful—it translates deal rationale into investor language. But it requires careful architecture.

The Core Mechanics: What Drives Accretion and Dilution

Accretion/dilution measures the impact of a transaction on the acquirer's earnings per share. A transaction is accretive if it increases EPS immediately, dilutive if it decreases EPS.

Four variables drive this:

1. Relative valuation gap: If you're buying a company at a lower multiple than your own trading multiple, it's typically accretive (all else equal). If you're buying at a higher multiple, it's dilutive.

Example: Acquirer trades at 12x EPS. Target trades at 8x EPS. Acquiring at 8x creates immediate earnings accretion because the acquired earnings are capitalized at a lower multiple.

2. Synergies: Cost and revenue synergies realized post-close increase combined earnings, driving accretion. When presenting accretion, distinguish between "synergy-free" accretion (based purely on relative valuations) and "synergy-inclusive" accretion (reflecting realistic synergy capture).

3. Financing costs: How the deal is financed dramatically impacts accretion. An all-cash deal funded by issuing equity (diluting the share count) is more dilutive than debt-financed. If you issue $500 million in equity at $30/share, you've created 16.7 million new shares—that's a 3-5% share count increase depending on existing shares outstanding. That counts as dilution.

4. Integration costs: One-time expenses (severance, system integration, facility consolidation) hit Year 1 earnings, creating Year 1 dilution. By Year 2-3, these costs are gone and synergies are flowing, creating accretion. A credible analysis shows Year 1 dilution and Years 2+ accretion.

Building the Analysis: Synergy-Free First

Start with a "synergy-free" accretion/dilution bridge. This shows what happens to EPS purely from the combination of two businesses, absent any synergies.

Step 1: Calculate target's standalone contribution

• Target's NTM EBITDA: $50 million
• Target's NTM EPS: $2.50 (after tax and interest on target's existing debt)

Step 2: Calculate acquirer's standalone contribution

• Acquirer's NTM EPS: $4.00

Step 3: Model combined company (no synergies, no financing impact yet)

• Combined EBITDA: Acquirer's $200M + Target's $50M = $250M
• Calculate combined company's pro-forma EPS

Step 4: Model financing impact

• If financed 50% debt, 50% equity:
  • Debt financing: $300M debt issuance, assuming 3.5% rate = $10.5M annual interest ($7.2M after-tax)
  • Equity financing: $300M at acquirer's $30 stock price = 10M new shares
  • New interest cost reduces earnings; new share count increases denominator
  • Combined effect: dilution of ~5-8% in Year 1

Step 5: Layer in synergies and one-time costs

• Year 1: Realize 30% of identified synergies, but incur $15M integration costs
• Year 2-3: Realize 75%+ of synergies, integration costs clear
• Show accretion/dilution for each year

Presenting the Analysis: The Waterfall Format

The clearest presentation is a waterfall that bridges from acquirer EPS to combined EPS:

Acquirer EPS (Year 1):                    $4.00
+ Target earnings contribution:           +$2.50
- Financing costs (interest):             -$0.35
/ Dilution from equity issuance:          /0.95x
+ Synergies (30% realization):            +$0.40
- Integration costs:                      -$0.25
Projected Combined EPS (Year 1):          $5.85 (46% accretive)

Wait—the calculation shows $5.85, but dividing by increased shares (due to equity issuance) modifies that. Let me recalculate more precisely:

Acquirer's Year 1 contribution: $4.00/share × existing shares Target's Year 1 contribution: net of interest on target's debt Combined earnings before financing: ~$6.50 Less: new interest on acquisition debt: -$0.35 Less: integration costs: -$0.25 Plus: synergies (30% of $40M identified = $12M): +$0.40 Combined pro-forma net income: ~$6.30 Divided by: combined shares (including dilution from equity issuance) Result: ~$5.85/share

The math is less important than the message. The waterfall shows: here's where we start, here's what adds to earnings, here's what reduces it, here's where we end up.

A More Practical Presentation Approach

In practice, most teams present accretion/dilution as a simple multi-year table:

| | Year 1 | Year 2 | Year 3 | |---|---|---|---| | Acquirer EPS | 4.00 | 4.30 | 4.65 | | Combined EPS (synergy-free) | 5.20 | 5.60 | 6.05 | | Less: Synergy phase-out | -0.15 | -0.10 | -0.05 | | Less: Integration costs | -0.25 | -0.05 | - | | Pro-forma combined EPS | 4.80 | 5.45 | 6.00 | | Accretion/(Dilution) % | 20% | 27% | 29% |

This table is clearer because it shows progression. Year 1 shows dilution despite synergies (because integration costs are heavy). By Year 2-3, the business is accretive as synergies flow and integration costs clear.

Sensitivity and Scenario Analysis

The strongest accretion/dilution analysis includes scenarios:

• Bear case: Synergies realize at 50% of expected, financing costs are higher due to market rates increasing
• Base case: Mid-point assumptions
• Bull case: Synergies realize above expectations, buyer achieves additional cost savings

Show each scenario's Year 1, Year 2, and Year 3 accretion/dilution. This demonstrates to the board: "Even in a bear case, we're accretive by Year 2. In the base case, we're accretive within 18 months."

The Critical Framing: Long-term vs. Short-term

The most common mistake is letting Year 1 dilution become a board distraction. Address it directly:

"Year 1 reflects integration costs and financing drag. Year 1 dilution is expected and manageable. By Year 2, as integration completes and synergies flow, the deal is highly accretive. Our analysis shows strong accretion over a 3-5 year hold period."

This framing resets expectations. Smart boards understand that M&A is a long-term investment, not a short-term EPS game. Presenting accretion progression across years (not just Year 1) aligns your analysis with appropriate investor mentality.

Real-World Nuances

Several details affect accretion/dilution and deserve mention in your presentation:

Write-up and amortization: When you acquire, you typically write up balance sheet items (goodwill, intangibles). This creates amortization expense that reduces post-close earnings. Conservative analysis includes this. Aggressive analysis sometimes excludes it ("non-GAAP basis"). Be clear which you're showing.

Tax impact of deal structure: M&A can be taxable or tax-free depending on how it's structured. Tax-free deals (typically stock-for-stock) don't create the same cash tax drag as taxable deals. Sophisticated analysis distinguishes these.

Working capital adjustments: The purchase agreement likely includes working capital adjustments—if target has more/less WC at close than assumed, purchase price adjusts. Model the cash impact.

Presentation Format and Consistency

Accretion/dilution slides often live in multiple places: the initial pitch deck, the process letter, the management presentation. Ensure that:

• The table structure is consistent across all documents
• Assumptions are consistent (if Year 2 synergies are 70% realization in the pitch, they're 70% in the management presentation, not 75%)
• Formatting is uniform (same number of decimal places, same color hierarchy)

Using standardized templates through tools like Poesius ensures that when the deal model is updated with new information (revised synergy estimates, updated financing terms), all presentations automatically reflect the new assumptions. This prevents the embarrassment of presenting different accretion/dilution numbers across different materials.

The Closer: Why This Deal Makes Sense

End your accretion/dilution analysis with a summary statement:

"This transaction is initially dilutive due to integration costs but becomes meaningfully accretive by Year 2 as synergies flow. Over a 3-5 year investment horizon, the deal delivers strong EPS growth and significantly enhances long-term shareholder value."

That's the message: short-term dilution is a feature of integration, not a flaw in deal logic. The real value emerges over time.